Navigation Links
3SBio Inc. to Present at the UBS Greater China Conference 2012
Date:1/9/2012

SHENYANG, China, Jan. 9, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced Mr. Bo Tan, 3SBio's chief financial officer will attend the UBS Greater China Conference 2012 in Shanghai on January 11, 2012. A copy of Mr. Tan's presentation will be archived at www.3sbio.com under the investor relations section.  

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and MP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor Contacts


Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. 3SBio Inc. Announces Results of 2011 Annual General Meeting
2. 3SBio Inc. Announces Unaudited First Quarter 2011 Results
3. 3SBio Inc. Schedules Unaudited First Quarter 2011 Results
4. 3SBio Inc. Schedules Unaudited Fourth Quarter and Fiscal Year 2010 Results
5. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
6. 3SBio Inc. Announces Unaudited Third Quarter Results
7. 3SBio Inc. Announces Unaudited Second Quarter Results
8. 3SBio Inc. Schedules Second Quarter 2010 Unaudited Financial Results
9. 3SBio Inc. Announces Filing of Form 20-F With SEC
10. 3SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010
11. 3SBio Announces Changes to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March 24, ... Maxwell Biotech Venture Fund (MBVF), today announced positive results ... to the standard drug therapy regimen in patients with ... molecule drug discovered by scientists at Sequella, Inc. ( ... of Health. A total of 140 ...
(Date:3/24/2017)... 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... China , today announced that its board of directors has ... the plan from March 27, 2017 to March 27, 2018. The amendment ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
(Date:3/24/2017)... WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ ... medical dermatology and aesthetics company, today announced that ... Financial Officer, effective March 24.   Peterson, who ... will succeed John Smither , who is retiring ... serve Sienna in an advisory capacity. Peterson joins Sienna ...
Breaking Biology Technology:
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):